Total Payments
$345,367
2023 Payments
$127.14
Companies
22
Transactions
529
Medicare Patients
144
Medicare Billing
$13,342
Payment Breakdown by Category
Other$226,959 (65.7%)
Consulting$65,643 (19.0%)
Travel$35,978 (10.4%)
Food & Beverage$9,005 (2.6%)
Research$7,572 (2.2%)
Education$210.01 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $226,959 | 90 | 65.7% |
| Consulting Fee | $65,643 | 27 | 19.0% |
| Travel and Lodging | $35,978 | 74 | 10.4% |
| Food and Beverage | $9,005 | 317 | 2.6% |
| Unspecified | $7,572 | 15 | 2.2% |
| Education | $210.01 | 6 | 0.1% |
Payments by Type
General
$337,795
514 transactions
Research
$7,572
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $127,311 | 134 | $0 (2021) |
| Genentech USA, Inc. | $47,595 | 38 | $0 (2021) |
| GENZYME CORPORATION | $44,966 | 59 | $0 (2019) |
| Celgene Corporation | $28,411 | 28 | $0 (2023) |
| EMD Serono, Inc. | $27,844 | 49 | $0 (2021) |
| Alexion Pharmaceuticals, Inc. | $19,367 | 34 | $0 (2019) |
| Acorda Therapeutics, Inc | $19,030 | 25 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $11,580 | 18 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $6,894 | 18 | $0 (2021) |
| Teva Pharmaceuticals USA, Inc. | $4,525 | 83 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $127.14 | 1 | Celgene Corporation ($127.14) |
| 2022 | $69.25 | 1 | E.R. Squibb & Sons, L.L.C. ($69.25) |
| 2021 | $36,944 | 27 | Biogen, Inc. ($24,172) |
| 2020 | $24,209 | 19 | Biogen, Inc. ($14,730) |
| 2019 | $110,935 | 137 | Biogen, Inc. ($25,619) |
| 2018 | $10,984 | 27 | Genentech USA, Inc. ($10,193) |
| 2017 | $162,098 | 317 | Biogen, Inc. ($62,590) |
All Payment Transactions
529 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/02/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $127.14 | General |
| Category: Neuroscience | ||||||
| 02/17/2022 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $69.25 | General |
| Category: Neuroscience | ||||||
| 12/07/2021 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,030.00 | General |
| Category: Neuroscience | ||||||
| 12/06/2021 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,955.00 | General |
| Category: NEUROLOGY | ||||||
| 12/06/2021 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | Cash or cash equivalent | $38.51 | General |
| Category: NEUROLOGY | ||||||
| 11/18/2021 | Genentech USA, Inc. | OCREVUS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,520.00 | General |
| Category: Immunology | ||||||
| 11/15/2021 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,955.00 | General |
| Category: NEUROLOGY | ||||||
| 11/15/2021 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | Cash or cash equivalent | $46.31 | General |
| Category: NEUROLOGY | ||||||
| 11/11/2021 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $104.27 | General |
| Category: Neuroscience | ||||||
| 11/04/2021 | Biogen, Inc. | TYSABRI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,955.00 | General |
| Category: NEUROLOGY | ||||||
| 11/04/2021 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | Cash or cash equivalent | $99.53 | General |
| Category: NEUROLOGY | ||||||
| 10/28/2021 | Biogen, Inc. | TYSABRI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,520.00 | General |
| Category: NEUROLOGY | ||||||
| 10/28/2021 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | Cash or cash equivalent | $23.16 | General |
| Category: NEUROLOGY | ||||||
| 10/21/2021 | Genentech USA, Inc. | OCREVUS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,520.00 | General |
| Category: Immunology | ||||||
| 09/09/2021 | Genentech USA, Inc. | OCREVUS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,520.00 | General |
| Category: Immunology | ||||||
| 08/19/2021 | Biogen, Inc. | TYSABRI (Biological) | Consulting Fee | Cash or cash equivalent | $1,695.00 | General |
| Category: NEUROLOGY | ||||||
| 05/17/2021 | Celgene Corporation | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,550.00 | General |
| Category: Neuroscience | ||||||
| 05/06/2021 | Biogen, Inc. | VUMERITY (Drug) | Consulting Fee | Cash or cash equivalent | $2,448.00 | General |
| Category: NEUROLOGY | ||||||
| 04/30/2021 | EMD Serono, Inc. | — | Food and Beverage | In-kind items and services | $15.38 | General |
| 04/27/2021 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,695.00 | General |
| Category: NEUROLOGY | ||||||
| 04/07/2021 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $41.33 | General |
| Category: NEUROSCIENCE | ||||||
| 03/28/2021 | Celgene Corporation | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Neuroscience | ||||||
| 03/27/2021 | Celgene Corporation | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Neuroscience | ||||||
| 03/26/2021 | EMD Serono, Inc. | — | Food and Beverage | In-kind items and services | $11.58 | General |
| 03/24/2021 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $7.55 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CDS - Acorda Therapeutics - Post Stroke Modality - Ampyra | Acorda Therapeutics, Inc | $5,556 | 7 |
| Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) | Biogen, Inc. | $2,016 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 3 | 73 | 102 | $25,882 | $7,999 |
| 2020 | 4 | 71 | 90 | $20,478 | $5,343 |
Total Patients
144
Total Services
192
Medicare Billing
$13,342
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 19 | 25 | $7,375 | $2,319 | 31.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 11 | 17 | $5,015 | $1,800 | 35.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 13 | 28 | $6,804 | $1,597 | 23.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 18 | 20 | $4,180 | $1,406 | 33.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 12 | 12 | $2,508 | $876.81 | 35.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 19 | 25 | $7,375 | $1,642 | 22.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 23 | 28 | $5,852 | $1,602 | 27.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 14 | 21 | $5,103 | $1,164 | 22.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 15 | 16 | $2,148 | $934.32 | 43.5% |
About Dr. Cary Twyman, MD
Dr. Cary Twyman, MD is a Clinical Neurophysiology healthcare provider based in Hershey, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407803141.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cary Twyman, MD has received a total of $345,367 in payments from pharmaceutical and medical device companies, with $127.14 received in 2023. These payments were reported across 529 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($226,959).
As a Medicare-enrolled provider, Twyman has provided services to 144 Medicare beneficiaries, totaling 192 services with total Medicare billing of $13,342. Data is available for 2 years (2020–2021), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical Neurophysiology
- Other Specialties Neurology
- Location Hershey, PA
- Active Since 05/28/2006
- Last Updated 07/03/2018
- Taxonomy Code 2084N0600X
- Entity Type Individual
- NPI Number 1407803141
Products in Payments
- LEMTRADA (Drug) $44,839
- ZINBRYTA (Biological) $42,286
- OCREVUS (Biological) $31,141
- TECFIDERA (Drug) $23,458
- TYSABRI (Biological) $20,154
- VUMERITY (Drug) $19,083
- Ozanimod (Drug) $17,160
- Non-Covered Product (Drug) $16,476
- AMPYRA (Drug) $16,208
- Mavenclad (Biological) $15,008
- ZEPOSIA (Drug) $14,754
- Rebif (Biological) $12,164
- Betaseron (Drug) $11,580
- COPAXONE (Drug) $4,413
- ACTHAR (Biological) $3,251
- MAYZENT (Drug) $2,448
- GILENYA (Drug) $2,031
- AUBAGIO (Drug) $126.64
- SOLIRIS (Drug) $86.32
- AUSTEDO (Drug) $84.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.